2Furburg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction [ J ]. Am J Cardiol, 1983,52:32c-36c.
3Gittlib SH, Achuff SC, Mellits ED, et al. Prophylactic antiarrhythmic therapy of high-risk survivors of myocardial infarction:lower mortality at 1 month but not at 1 year[ J ]. Circulation, 1987,75:792-799.
4Echt DS,Liebson PR,Mitchell LB.et al. Morbidity and morbidity in patients receiving flecainide or placebo. The Cardiac Arrhythmia Suppression Trial [ J ]. N Engl J Med, 1991,324:781-788.
5The Cardiac Arrhythmic Suppression Trial Ⅱ Investigators. Effect of the antiarrhythmic agent moricizine in suvival after myocardial infarction [ J ]. N Engl J Med ,1992,327:227-233.
6Wellens HJ. Cardiac arrhythmias:The quest for a cure A historical perspective[ J ]. JACC,2004,44(6) :1155-1163.
7Teo KK, Yusuf S, Furburg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled clinical trials[ J ]. JAMA, 1993,270 : 1589-1595.
8Burkart F,Pfister M ,Kiowski W, et al. Effect of antiarrhythmic therapy on mortality of survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias : Basal Antiarrhythmic Study of Infarct Survival (BASIS) [ J ]. J Am Cardiol, 1990,16 : 1711-1718.
9Pfisterer ME, Kiowski W, Brunner H, et al. Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction [ J ]. Circulation, 1993,87 : 309 -311.
10Julian DG,Camm AJ,Frengin G,et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction : EMIAT[ J ]. Lancet, 1997,349:667-674.
4Foo K,Cooper J,Deaner A,et al.A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes.Heart,2003,89(5):512-516.
5Zhou Y,Wang Y,Qiao S.Apelin:a potential marker of coronary artery stenosis and atherosclerotic plaque stability in ACS patients[J].Int Heart J,2014(3):204-212.
6Chung H,Kwon HM,Kim JY,et al.Lipoprotein-associated phospholipase a2is related to plaque stability and is a potential biomarker for acute coronary syndrome[J].Yonsei Med J,2014(6):1507-1515.
7Foo K,Cooper J,Deaner A,et al.A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes[J].Heart,2003(5):512-516.
8Heeschen C,Dimmeler S,Hamm CW,et al.Pregnancy associated plasma protein-A levels in patients with acute coronary sydromes:comparison with markers of systemic infammation,platele cutivation and myocardial necrosis[J].J Am Coll Cardiol,2005(2):229-237.
10Cesari M,Penninx BW,Newman AB,et al.Inflammatory markers and onset of cardiovascular events results from the health ABC study[J].Circulation,2003(19):2317-2322.
